






General defect	Main mechanisms	Key factors	
Decrease in cortisol production			
Altered adrenal synthesis of cortisol	Necrosis/hemorrhage	Acute kidney failure; hypo-coagulation; disseminated intravascular coagulation; cardiovascular collapse; tyrosine kinase inhibitors	
	Decreased availability of esterified cholesterol	Depletion in adrenal storage regulated by annexin A1–formyl peptide receptors Down regulated scavenger receptor-B1	
	Inhibition of steroidogenesis	Immune cells/Toll-like receptors/cytokines	
		Drugs (e.g., sedatives, corticosteroids)	
		ACTH-like molecules (e.g., corticostatins)	
Altered synthesis of CRH/ ACTH	Necrosis/hemorrhage	Cardiovascular collapse; disseminated intravascular coagulation; treatment with vasopressor agents	
	Inhibition of ACTH synthesis	Glial cells/nitric oxide mediated neuronal apoptosis	
		Increased negative feedback from circulating cortisol following up regulation of ACTH-independent mechanisms of cortisol synthesis	
		Drugs (e.g., sedatives, anti-infective, psychoactive agents)	
		Inappropriate cessation of glucocorticoid treatment	
Alteration of cortisol metabolism	Decreased cortisol transport	Down regulation of liver synthesis of cortisol-binding globulins and albumin	
	Reduced cortisol breakdown	Decreased expression and activity of the glucocorticoid-inactivat- ing 5-reductase enzymes in the liver with putative role of bile acids; Decreased expression and activity of the hydroxysteroid dehydrogenase in the kidney	C
Target tissue resistance to cortisol	Inadequate glucocorticoid receptor alpha (GR-α) activity	Multifactorial etiology including reduced GR- $\!\alpha$ density and transcription and excessive NF-kappa B activation	
























Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 28-Day all-cause mortality	50	11233	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.84, 0.99]
10 90-Day all-cause mortality	7	5934	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.87, 1.00]
11 Long-term mortality	7	6236	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.91, 1.03]
12 Intensive care unit mortality	18	7267	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.83, 0.96]
13 Hospital mortality	26	8183	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.82, 0.99]


			•		
Study or subgroup	Treatment	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% Cl		4-H, Random, 95% CI
Sprung 1984	25/43	6/16		1.52%	1.55[0.78,3.06]
Bone 1987	85/130	83/114	-	10.85%	0.9[0.76,1.06]
Bollaert 1998	15/22	4/19		0.87%	3.24[1.3,8.1]
Briegel 1999	17/20	12/20	++	3.76%	1.42[0.95,2.12]
Chawla 1999	16/23	9/21	+++	2.14%	1.62[0.92,2.85]
Annane 2002	60/151	40/149		5.08%	1.48[1.06,2.06]
Oppert 2005	14/18	16/23		4.36%	1.12[0.78,1.61]
Sprung 2008	186/251	145/248	+	13.04%	1.27[1.12,1.44]
Hu 2009	33/38	27/39		7.56%	1.25[0.98,1.6]
Sabry 2011	38/40	26/40		7.74%	1.46[1.15,1.85]
Arabi 2011	24/39	14/36		2.83%	1.58[0.98,2.55]
Gordon 2014	19/31	13/30	+++	2.67%	1.41[0.86,2.32]
Huang 2014	12/20	22/40		3.09%	1.09[0.69,1.72]
Menon 2017	3/23	3/26	•	0.34%	1.13[0.25,5.06]
Annane 2018	501/614	474/627	*	16.7%	1.08[1.02,1.14]
Venkatesh 2018	1594/1898	1274/1902	•	17.46%	1.25[1.21,1.3]
Total (95% CI)	3361	3350	•	100%	1.23[1.13,1.34]
Total events: 2642 (Treatmen	t), 2168 (Control)				
Heterogeneity: Tau ² =0.01; Ch	i ² =43.87, df=15(P=0); l ² =65.81	%			
Test for overall effect: Z=4.66	(P<0.0001)				
		Favours control 0.2	0.5 1 2	5 Favours corticosteroid:	

Study or subgroup	Tr	eatment		Control	Mean Difference	Weight	Mean Difference
study of subgroup	N	Mean(SD)	N	Mean(SD)	Random, 95% CI	neight	Random, 95% CI
Annane 2002	151	7.5 (3)	149	9.5 (4)	-+-	15.63%	-2[-2.8,-1.2]
Annane 2018	440	6 (4)	414	7 (5)		19.32%	-1[-1.61,-0.39]
Arabi 2011	39	11.7 (4.2)	36	12.3 (4.2)	+	5.03%	-0.6[-2.5,1.3]
Cicarelli 2007	15	9 (4)	14	9 (5)		1.88%	0[-3.31,3.31]
Gordon 2014	31	6.2 (4.3)	30	6.5 (3.5)		4.77%	-0.3[-2.26,1.66]
Mirea 2014	117	7.7 (6)	54	8.6 (5.2)		5.73%	-0.92[-2.68,0.84]
Oppert 2005	23	6 (4)	25	8 (4)		3.74%	-2[-4.27,0.27]
Rinaldi 2006	20	1(4)	20	2 (4)		3.19%	-1[-3.48,1.48]
Sabry 2011	40	1 (0.5)	40	3 (0.9)	+	25.21%	-2[-2.32,-1.68]
Sprung 2008	251	6.1 (4.4)	248	7.1 (4.8)		15.5%	-1[-1.81,-0.19]
Fotal ***	1127		1030		•	100%	-1.37[-1.84,-0.9]
Heterogeneity: Tau ² =0.2; Ch	i ² =17.03, df=9(P=	0.05); I ² =47.16%			-		
Test for overall effect: Z=5.7							

					rticosteroids versus place hospital stay for all partic		
Study or subgroup		eatment		Control	Mean Difference	Weight	Mean Difference
Annane 2002	N 151	Mean(SD) 20 (21)	N 149	Mean(SD) 25 (22)	Random, 95% Cl	4,51%	Random, 95% CI -5[-9.87,-0.13]
Annane 2002 Annane 2018		32.6 (38.2)	627	25 (22)		4.51%	-5[-9.87,-0.13] 3.8[-0.57,8.17]
Annane 2018 Arabi 2011	614 39	32.6 (38.2) 22 (13.4)	36	28.8 (40.4) 26.4 (23.6)	4.	1.86%	-4.4[-13.18,4.38]
Blum 2015	39	8.5 (5.8)	393	26.4 (23.6) 10 (6.9)		1.86%	-4.4[-13.18,4.38] -1.5[-2.39,-0.61]
Bollaert 1998	392	35 (31)	393 19	24 (26)		0.53%	-1.5[-2.39,-0.61] 11[-6.45,28.45]
Chawla 1999	22	35 (31)	21	24 (26) 21 (14.5)		2.06%	-4.1[-12.35,4.15]
Confalonieri 2005	23	16.9 (13.3)	21	21 (14.5) 25 (16.8)		2.18%	-4.1[-12.35,4.15] -7.3[-15.27,0.67]
Fernández-Serrano 2011	23	11.8 (7.2)	23	15 (7.5)		5.89%	-3.25[-7.11,0.61]
Gordon 2014	31	34 (32.8)	30	35.9 (25)		0.74%	-1.9[-16.51.12.71]
Gordon 2016	208	15 (20)	213	16 (23)		5.5%	-1[-5.11,3.11]
Keh 2016	190	26 (22.2)	190	25 (17.8)	•	5.6%	1[-3.05,5.05]
Ly 2017	58	23.7 (36.8)	60	21.7 (21.7)	4	1,26%	2[-8.95,12.95]
Meduri 2007	42	13 (19)	19	20.5 (30)		0.74%	-7.5[-22.16,7.16]
Meijvis 2011	151	6.5 (9.3)	153	7.5 (13.8)	`	8.15%	-1[-3.64,1.64]
Menon 2017	23	10.7 (15.2)	26	9.6 (10.2)	↓	2.49%	1.1[-6.25,8.45]
Mirea 2014	117	17.4 (10.1)	54	17.9 (11.7)	•	6.29%	-0.51[-4.13,3.11]
Nagy 2013	29	11.5 (1.7)	30	16.4 (2.3)	←	11.42%	-4.9[-5.93,-3.87]
Snijders 2010	104	10 (12)	109	10.6 (12.8)	·	6.8%	-0.6[-3.93,2.73]
Sprung 2008	251	34 (41)	248	34 (37)	•	2.78%	0[-6.85,6.85]
Torres 2015	60	14.5 (14.5)	58	14.9 (17.6)	< + +	3.54%	-0.4[-6.23,5.43]
Venkatesh 2018	1853	39 (52.6)	1860	43 (52.6)	← +	6.7%	-4[-7.38,-0.62]
Yildiz 2002	20	14 (9.6)	20	13 (6.7)	•	4.21%	1[-4.13,6.13]
Total ***	4429		4366			100%	-1.63[-2.93,-0.33]
Heterogeneity: Tau ² =3.57; Chi ²	² =51.44, df=21(P=0); I ² =59.18%					
Test for overall effect: Z=2.46(F	P=0.01)						
			Favours c	orticosteroids	-5 -2.5 0 2.5	5 Favours co	ntrol



All C	orticosteroids A	re Not Equiva	lent
Molecules	Glucocorticoid activity	Mineralocorticoid activity	Non-genomic
	relative to hydrocortisone	relative to hydrocortisone	effects relative to
			hydrocortisone
Hydrocortisone	1	1	1
Prednisone	4	0.8	4
Prednisolone	4	0.8	4
Methylprednisolone	5	0.5	14
Betamethasone	25	0	-0
Dexamethasone	25	0	20
Fludrocortisone	10	125	\$











Table 3. Adverse Events.*				
Event	Placebo (N = 627)	Hydrocortisone plus Fludrocortisone (N = 614)	Relative Risk (95% CI)†	P Value
≥1 Serious event by day 180 — no./total no. (%)	363/626 (58.0)	326/614 (53.1)	0.92 (0.83-1.01)	0.08
≥1 Serious bleeding event by day 28 — no./total no. (%)	119/626 (19.0)	127/614 (20.7)	1.09 (0.87-1.36)	0.46
Gastroduodenal bleeding — no./total no. (%)	45/626 (7.2)	39/614 (6.4)	0.88 (0.58-1.34)	0.56
≥1 Episode of superinfection by day 180 — no./total no. (%)	178/626 (28.4)	191/614 (31.1)	1.09 (0.92-1.30)	0.30
Site of superinfection — no./total no. (%)				
Lung	116/626 (18.5)	127/614 (20.7)	1.12 (0.89–1.40)	0.34
Blood	48/626 (7.7)	49/614 (8.0)	1.04 (0.71-1.53)	0.84
Catheter-related	37/626 (5.9)	40/614 (6.5)	1.10 (0.71–1.70)	0.66
Urinary tract	33/626 (5.3)	40/614 (6.5)	1.24 (0.79-1.93)	0.35
Other	57/626 (9.1)	70/614 (11.4)	1.25 (0.90–1.74)	0.18
New sepsis — no./total no. (%)	122/626 (19.5)	134/614 (21.8)	1.12 (0.90-1.39)	0.31
New septic shock — no./total no. (%)	103/626 (16.5)	109/614 (17.8)	1.08 (0.84–1.38)	0.54
Hyperglycemia				
≥1 Episode of blood glucose levels ≥150 mg/dl by day 7 — no./total no. (%)	520/626 (83.1)	547/614 (89.1)	1.07 (1.03–1.12)	0.002
No. of days with ≥1 episode of blood glucose levels ≥150 mg/dl by day 7				
Mean	3.4±2.5	4.3±2.5	_	<0.00]
Median (IQR)	3 (1-6)	5 (26)		
Neurologic sequelae by day 28 — no./total no. (%)‡				
Last MDRS score >1	130/626 (20.8)	153/614 (24.9)	1.20 (0.98-1.47)	0.08
Last MDRS score >3	92/626 (14.7)	108/614 (17.6)	1.20 (0.93–1.54)	0.17
Last MDRS score = 5	65/626 (10.4)	73/614 (11.9)	1.15 (0.84-1.57)	0.40




























Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
4 28-Day all-cause mortality by subgroups based on treatment dose/duration	44	10812	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.86, 0.97]
4.1 Long course of low-dose cor- ticosteroids	39	9902	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.86, 0.97]
4.2 Short course of high-dose corticosteroids	5	910	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.80, 1.16]


Dutcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
28-Day all-cause mortality ased on mode of drug adminis- ration	45	9978	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.82, 0.99]
5.1 Intravenous bolus	27	4749	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.83, 1.02]
.2 Continuous infusion	18	5229	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.66, 1.07]
328-Day all-cause mortality based on mode of drug termina- ion	47	10906	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.83, 1.00]
5.1 Without taper off	30	8770	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.78, 0.98]
.2 With taper off	17	2136	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.92, 1.18]





Study or subgroup	Treatment n/N	Control n/N	Risk Ratio M-H, Random, 95% Cl	Weight	Risk Ratio M-H, Random, 95% CI
1.8.1 Sepsis	.,	.,	in the manual sector of		
Bone 1987	65/191	48/190		22.47%	1.35[0.98,1.84
VASSCSG 1987	23/112	24/111	_	12.78%	0.95[0.57,1.58
Luce 1988	22/38	20/37		17.29%	1.07[0.72,1.6
Slusher 1996	6/36	4/36		- 3.15%	1.5[0.46,4.87
Yildiz 2002	8/20	12/20		8.95%	0.67[0.35,1.27
Rinaldi 2006	6/26	7/26		4.7%	0.86[0.33,2.21
Meduri 2009	22/48	4/31	+	4.53%	3.55[1.35,9.32
Yildiz 2011	16/27	15/28		14.39%	1.11[0.69,1.76
Huang 2014	4/20	7/20 🔶		3.82%	0.57[0.2,1.65
Keh 2016	15/171	14/170		7.91%	1.07[0.53,2.14
Subtotal (95% CI)	689	669	•	100%	1.1[0.89,1.37
Total events: 187 (Treatment), Heterogeneity: Tau ² =0.03; Chi ³	² =12.04, df=9(P=0.21); I ² =25.	25%			
Test for overall effect: Z=0.88(F	P=0.38)				




















	CORTICO	OSTE	ROI	DS	- ^	۸OR	TALITY - C	DBSERVATIONAL	0
-	COHOR	Experim		Contr		147-1-ba	Risk Ratio	Risk Ratio	
	Study or Subgroup Zha 2020	Events 0	10tal	Events	10tal 20	weight	M-H, Random, 95% Cl Not estimable	M-H, Random, 95% Cl	
	Ramiro 2020	10	86	33	86	7.9%	0.30 [0.16, 0.58]		
	Salton 2020	6	83	21	90	6.7%	0.31 [0.13, 0.73]		
	Li 2020	14	67	30	52	8.5%	0.36 [0.22, 0.61]		
	Cruz 2020	55	396	16	67	8.6%	0.58 [0.36, 0.95]		
	Callejas 2020	6	83	1	9	2.7%	0.65 [0.09, 4.82]		
	Ruiz-Irastorza 2020	4	61	18	181	5.8%	0.66 [0.23, 1.87]		
	Wu 2020	21	50	21	34	9.0%	0.68 (0.45, 1.03)		
	Mikulska 2020	13	45	23	66	8.3%	0.83 [0.47, 1.46]		
	Rivera 2020	30	100		750	9.4%	1.13 [0.82, 1.55]		
	Guan 2020	5	204		895	6.2%	1.15 [0.44, 3.06]		
	Liu 2020	181	409		365	9.8%	1.43 [1.18, 1.72]	+	
	Zhou 2020	26	57			8.9%	2.18 [1.41, 3.37]		
	Wang 2020	65	241	13	205	8.3%	4.25 [2.42, 7.49]		
	Total (95% CI)		1893		2954	100.0%	0.86 [0.58, 1.27]	•	
	Total events Heterogeneity: Tau ² Test for overall effect				(P < 0.0	10001); I²=	87%	0.05 0.2 1 5 20 Favours Control	0
			(D	C	D	0	0	





	0						0
0	Corticoster	oids — /	Morta Control	lity-	RCTs Risk Ratio	Risk Ratio	
				Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
-	2.1.1 Placebo controlled a						
	Dequin 2020	11 75	20 73	2.1%	0.54 [0.28, 1.04]		
	Jeronimo 2020	72 194	76 199	7.7%	0.97 [0.75, 1.25]		
	COVID-STEROID 2020	6 15	2 14	0.2%			
	Subtotal (95% CI) Total events	284 89	286 98	9.9%	0.92 [0.73, 1.16]	-	
	Total events Heterogeneity: Chi ^a = 5.10, Test for overall effect: Z = 0	df = 2 (P = 0.08);					
	2.1.2 Open label trials						
	Angus 2020	78 278	33 99	5.0%	0.84 [0.60, 1.18]		
	Horby 2020	482 2104	1110 4321		0.89 [0.81, 0.98]		
	Tomazini 2020	85 151	91 148	9.4%	0.92 [0.76, 1.11]		
	STEROIDS SARI 2020	13 24	13 23	1.4%	0.96 [0.57, 1.60]		
	DEXA-COVID-19 2020 Subtotal (95% CI)	2 7 2564	2 12 4603	0.2% 90.1%	1.71 [0.31, 9.61] 0.89 [0.82, 0.97]		
	Total events	660	1249	50.176	0.05 [0.02, 0.57]	•	
	Heterogeneity: Chi ² = 0.80, Test for overall effect: Z = 2	df = 4 (P = 0.94);					
	Total (95% CI)	2848	4889	100.0%	0.90 [0.83, 0.97]	•	
	Total events	749	1347		0.00 [0.00, 0.07]	•	0
	Heterogeneity: Chi ² = 5.98,						
	Test for overall effect: Z = 2	.77 (P = 0.006)				Favours Conticosteroids Favours Control	-
	Test for subgroup difference	ces: Chi² = 0.05, d	lf = 1 (P = 0.82)	²=0%			
				0			
			0				
			-	~	0	0	

	Corticosteroids – SAEs- RCTs	C
\bigcirc	Experimental Control Risk Ratio Risk Ratio Risk Ratio Att Anton 1956 CI Att Ratio 95% CI 22.1 Secondary bacterial inflections	
	2.2.1 secondary bacterial infections 151 43 148 22.6% 0.75 [0.51, 1.11] Dequin 2020 33 151 43 148 22.6% 0.75 [0.51, 1.11] Leronin 2020 74 73 21.6% 0.91 [0.51, 1.36] Jeronin 2020 74 194 57.9% 0.99 [0.77, 1.27] Subtotal (95% CT) 420 7420 100.0% 0.91 [0.76, 1.10] Total events 0.00, Ch ² = 1.30, df ² = 2 (² = 0.52); l ² = 0% 156 166 (² = 0.39) Test for overall effect Z = 0.96 (² = 0.39) 169.6% 169.6% 169.6%	
	2.2.2 Delayed viral clearance Jeronimo 2020 61 117 50 95 100.0% 0.99 [0.77, 1.28] Subtotal (9% Ct) 117 50 100.0% 0.99 [0.77, 1.28] Total events 61 50 Total events 61 50 100.0% 0.99 [0.77, 1.28] Total events 100.0%	
	2.2.3 Proportion of patients with ventilator associated pneumonia Tornazini 2020 19 151 29 148 49.0% 0.64 [0.36, 1.09] Dequin 2020 22 75 20 73 51.0% 0.64 [, 7.8] Subtotal (95% C) 226 221 100.0% 0.83 [0.50, 1.38] Total events, Tau" = 0.06; Chi" = 1.85, df = 1 (P = 0.17); IP = 46% Test for overall effect Z = 0.7 (P = 0.48)	
	2.2.4 Proportion of patients with bacteremia Dequin 2020 5 75 8 73 27.1% 0.61 (0.21, 1.77) Jerroimo 2020 9 108 7 88 34.7% 1.05 (0.41, 2.70) Tomszint 2020 10 151 8 34.7% 1.05 (0.41, 2.70) Tomszint 2020 10 151 8 36.2% 1.23 (0.50, 1.02) Tomszint 2020 10 151 9 10.0% (0.55, 1.60) 100 Total events 2.4 2.3 2.3 1.05 (0.41, 0.20) 100 Test for overall efect Z > 0.14 (0.40 (0.80) P = 0% 100 1.04 (0.40 (0.80) 100	0
	0.1 0.2 0.5 2 Favours Controsteroids) Favours Co	ontrol 5 10

